Spyre Therapeutics, Inc.
NASDAQ: SYRE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cameron Turtle
- Employees
- 73
- Headquarters
- Waltham, United States
- IPO year
- 2016
- Market cap
- $5.3B
- Website
- https://www.spyre.com
Loading SYRE…
Loading profile data…Frequently asked questions about SYRE
What does Spyre Therapeutics, Inc. (SYRE) do?
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin....
Where does SYRE trade?
Spyre Therapeutics, Inc. (SYRE) trades on the NASDAQ Capital Market.
What sector is SYRE in?
Spyre Therapeutics, Inc. (SYRE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Spyre Therapeutics, Inc.?
Cameron Turtle is the chief executive officer of Spyre Therapeutics, Inc. (SYRE).
Where is Spyre Therapeutics, Inc. headquartered?
Spyre Therapeutics, Inc. is headquartered in United States.
Does SYRE pay a dividend?
Spyre Therapeutics, Inc. (SYRE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SYRE go public?
Spyre Therapeutics, Inc. (SYRE) completed its initial public offering in 2016.